Clinical Scorecard: Link Between SGLT2 Inhibitor Administration and the Incidence of Sepsis-Related Cardiomyopathy in Individuals with Type 2 Diabetes: A Propensity-Matched Analysis

At a Glance

Key Highlights

• SICM affects approximately 20% of septic patients and is linked to increased short-term mortality.
• SGLT2 inhibitors have demonstrated cardiovascular benefits beyond glycemic control, including heart failure risk reduction.
• This study used propensity score matching comparing SGLT2is to DPP4is to evaluate the association with SICM incidence in T2D patients with sepsis.

Guideline-Based Recommendations

Diagnosis

• Identify SICM using ICD-10 codes for cardiomyopathy, heart failure, acute pulmonary edema, or intravenous loop diuretic administration within 30 days post-infection.

Management

• Consider baseline use of SGLT2 inhibitors in T2D patients to potentially reduce SICM risk during sepsis.
• Use DPP4 inhibitors as a comparator due to their neutral cardiovascular profile.

Monitoring & Follow-up

• Monitor for cardiovascular dysfunction during sepsis in T2D patients, including signs of myocardial injury and heart failure.
• Follow patients for up to 365 days post-infection for all-cause mortality, hospitalization, and major adverse cardiovascular events.

Risks

• SICM is associated with higher short-term mortality in septic patients.
• Potential confounding factors include baseline comorbidities and medication use; propensity score matching is recommended to balance these.

Patient & Prescribing Data

Adults with type 2 diabetes and documented infection treated with SGLT2 inhibitors or DPP4 inhibitors within 3 months prior to infection.

Baseline SGLT2 inhibitor use may be associated with a lower risk of developing SICM compared to DPP4 inhibitors, supporting their cardioprotective role in sepsis.

Clinical Best Practices

• Use propensity score matching to minimize confounding when comparing cardiovascular outcomes between glucose-lowering therapies.
• Assess baseline inflammatory markers and comorbidities to inform risk stratification for SICM.
• Incorporate SGLT2 inhibitors in T2D management plans considering their potential benefits in sepsis-related cardiac dysfunction.

References

• Sepsis and organ dysfunction overview
• Cardiovascular dysfunction in sepsis
• SGLT2 inhibitors cardiovascular benefits
• Propensity score matching methodology
• Clinical coding for SICM and outcomes